Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1652724/000119312523241312/d538189d8k.htm
Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1652724/000119312523241312/d538189d8k.htm
Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Lucira Health, Inc..
Lucira Health, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:
Financial Statements, Disclosures and Schedules
Inside this 8-K Corporate News
Material Contracts, Statements, Certifications & more
Lucira Health, Inc. provided additional information to their SEC Filing as exhibits
Ticker: LHDXQEvents:
CIK: 1652724
Form Type: 8-K Corporate News
Accession Number: 0001193125-23-241312
Submitted to the SEC: Mon Sep 25 2023 4:01:01 PM EST
Accepted by the SEC: Mon Sep 25 2023
Period: Tuesday, September 19, 2023
Industry: In Vitro And In Vivo Diagnostic Substances